Biopharmaceutical CDMO Rentschler Biopharma has announced that it will begin construction on a new buffer media station at its company HQ in Laupheim, Germany.
The novel building will aim to increase production efficiency of the site's overall production efficiency, while also ensuring that the company is prepared for long-term growth.
The four-storey buffer media station will span 34,000m2 and is estimated to be fully operational by 2028.
Rentschler's new addition to the Laupheim site will meet the highest quality and automation standards globally, while also being sustainability-driven.
There will be three media tanks and six buffer tanks incorporated into the facility, allowing for the commercial production of buffer solutions and media.
To ensure hygiene and reduce cross-contamination risks, buffer and media preparation will be performed in separate areas.
An in-house logistics and piping system will also support the company's upstream and downstream processes.
Construction is expected to commence in the first half of 2025, with the site's operational launch being estimated to be in late 2027.
Rentschler Biopharma's CEO, Benedikt von Braunmühl, commented: “This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries."
"While our focus remains on strengthening global partnerships," Benedikt continued, "this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.”
The company's Chief Operating Officer, Christiane Bardroff, added: “This project is not just an investment in our infrastructure — it's a fundamental part of our work. We're creating value sustainably for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and further afield. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands.”
[Image credit: Rentschler Biopharma]
